U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death

Go back to U.S. Calls for Pause of J&J (JNJ) Vaccine After Clotting Cases, Including One Death

Joint CDC and FDA Statement on Johnson & Johnson (JNJ) COVID-19 Vaccine

April 13, 2021 7:12 AM EDT

The following statement is attributed to Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research and Dr. Anne Schuchat, Principal Deputy Director of the CDC

As of April 12, more than 6.8 million doses of the Johnson & Johnson (Janssen) (NYSE: JNJ) vaccine have been administered in the U.S. CDC and FDA are reviewing data involving six reported U.S. cases of a rare and severe type of blood clot in individuals after receiving the J&J vaccine. In these cases, a type of blood clot called cerebral venous... More